Rochester, MN, USA—Resoundant, Inc. announced today the appointment of Roderic I. Pettigrew, MD, PhD to its Board of Directors.
"We’re honored and thrilled to have Dr. Pettigrew join the Resoundant Board," said Richard L. Ehman, MD, professor of Radiology and the Blanche R. & Richard J. Erlanger Professor of Medical Research at Mayo Clinic and CEO of Resoundant, Inc.
“Dr. Pettigrew brings a remarkable combination of technologic, scientific, and global policy expertise to our team. He is a true visionary who has guided one of the most innovative and transformative medical portfolios in the world. His insight will be a tremendous asset to Resoundant.”
Rochester, MN, USA— The COVID-19 pandemic is creating extraordinary challenges for our families, healthcare systems, and society as a whole. Our thoughts are with the communities impacted by the outbreak as well as the healthcare professionals working around the clock to help those most in need.
Status of Resoundant Operations
As a critical business in the healthcare and medical technology sector, Resoundant remains open and fully operational. Global demand for MR Elastography technology continues and Resoundant is working hard to ensure that our customers’ needs are met. As this crisis continues to unfold, our team remains focused on ensuring business contin...
• Liver parenchymal stiffness measured by MRE predicts early recurrence of treated HCC under Milan criteria.
• A liver stiffness > 5.5 kPa was associated with worse recurrence-free survival.
• Patients with high pre-treatment LS may benefit from stringent follow-up.
Magnetic resonance elastography (MRE) is a non-invasive tool for measuring liver stiffness (LS) with high diagnostic accuracy. This study investigated whether quantified LS by MRE could predict early recurrence of patients with hepatocellular carcinoma (HCC) within the Milan criteria.
A prospectively collected cohort, which included the HCC patients who underwent MRE...